LLY · News · 20260817N
Acquisition - AtaiBeckley Deal
ELI LILLY & Co · 2026-08-17 · Importance 37 · Surprise 42 · In source text
Lilly’s proposed acquisition of AtaiBeckley is subject to an investor investigation by Kahn Swick & Foti into the adequacy of the transaction’s price and process. Under the proposed terms, AtaiBeckley shareholders would receive $6.75 per share in cash. Shareholders may also receive a contingent value right worth up to $2.50 per share, creating potential total consideration of $9.25 per share.
Key facts
- Eli Lilly & Co is the buyer in the proposed sale of AtaiBeckley in which AtaiBeckley shareholders will receive $6.75 per share in cash plus up to $2.50 per share in the form of a Contingent Value Right. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | probable | — | Eli Lilly & Co is the buyer in the proposed sale of AtaiBeckley in which AtaiBeckley shareholders will receive $6.75 per share in cash… |
| liability | negative | contingent | — | Eli Lilly & Co is the buyer in the proposed sale of AtaiBeckley in which AtaiBeckley shareholders will receive $6.75 per share in cash… |